EXAI News and Press, Exscientia Limited

2024-07-03 03:10:00 ET Summary The BioRevolution is a strategy focused on challenging and evolving various aspects of human life, including health care, food production, energy generation and data storage, through biological advancements. At WisdomTree, we have the WisdomTree BioR...

2024-06-10 16:32:01 ET Summary Exscientia is using AI to improve drug discovery and address the low returns on investments in the pharmaceutical industry. While preclinical data generally looks promising, it is too early to know the overall impact of AI on drug discovery. Whil...

2024-06-08 04:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-06 09:08:00 ET Summary We recently rebalanced the WisdomTree Artificial Intelligence & Innovation Index, which is tracked by the WisdomTree Artificial Intelligence & Innovation Fund. The top 10 holdings in WTAI reflect the importance of big platform companies and t...

— AI drug design pioneer John P. Overington, Ph.D., appointed to Chief Technology Officer to maximise strategic technology integration and application — — Maria-Louise Fjällskog, M.D., Ph.D., appointed interim Chief Medical Officer, adding extensive oncology ...

Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in the following upcoming investor conferences in June: Barclays Digital and Disruptive Technology Conference. Panel on Tuesday, June 11, 2024 at 9:45 a.m. BST in London, England G...

2024-05-27 09:40:00 ET Summary Google DeepMind and Isomorphic Labs have recently unveiled an exciting new breakthrough, AlphaFold 3. AlphaFold 3 employs advanced AI algorithms to accurately model molecular structures and interactions. Beyond drug discovery, AlphaFold 3’...

2024-05-22 00:03:06 ET Summary Exscientia plc's stock has underperformed the biotechnology and IT sectors, despite owning a tech platform attracting big pharma. The company uses AI to accelerate drug development and reduce time to market, potentially improving success rates. T...

2024-05-21 11:27:43 ET More on Exscientia Exscientia plc (EXAI) Q4 2023 Earnings Call Transcript Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade) Exscientia FY 2023 Earnings Preview Anagenex expands leadership team with a...

2024-05-21 07:03:04 ET More on Exscientia Exscientia plc (EXAI) Q4 2023 Earnings Call Transcript Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade) Exscientia FY 2023 Earnings Preview Anagenex expands leadership team with a...